While healthcare has underperformed the broader market, Julien Nono-Womdim, VP, Portfolio Research at TD Asset Management tells MoneyTalk’s Greg Bonnell there may be pockets of opportunity.
New technologies focused on cancer and other disease areas may be poised to propel the biotech sector forward. John Hall, Investment Analyst for U.S. Biotech, T. Rowe Price, joined MoneyTalk’s Anthony Okolie to discuss.
